WO2002102743A3 - Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel - Google Patents
Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel Download PDFInfo
- Publication number
- WO2002102743A3 WO2002102743A3 PCT/DE2002/002260 DE0202260W WO02102743A3 WO 2002102743 A3 WO2002102743 A3 WO 2002102743A3 DE 0202260 W DE0202260 W DE 0202260W WO 02102743 A3 WO02102743 A3 WO 02102743A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- acetic acid
- alkyl esters
- amino alkyl
- acid amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002451638A CA2451638A1 (en) | 2001-06-17 | 2002-06-17 | Deuterated n-substituted and .alpha.-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds |
HU0400213A HUP0400213A3 (en) | 2001-06-17 | 2002-06-17 | Deuterated n-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds |
IL15941002A IL159410A0 (en) | 2001-06-17 | 2002-06-17 | DEUTERATED N-SUBSTITUTED AND alpha-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
JP2003505289A JP2004534802A (ja) | 2001-06-17 | 2002-06-17 | 重水素化N−及びα−置換ジフェニルアルコキシ酢酸アミノアルキルエステル並びにこれを含有する医薬品 |
US10/481,153 US20040242887A1 (en) | 2001-06-17 | 2002-06-17 | Deuterated n-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds |
NZ53035202A NZ530352A (en) | 2001-06-17 | 2002-06-17 | Deuterated N-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds |
KR10-2003-7016441A KR20040020926A (ko) | 2001-06-17 | 2002-06-17 | 중수소화된 엔-치환 및 α-치환 디페닐알콕시 아세트산아미노 알킬 에스테르 및 이 화합물을 포함한 의약품 |
EP02752970A EP1397327A2 (de) | 2001-06-17 | 2002-06-17 | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel |
IS7061A IS7061A (is) | 2001-06-17 | 2003-11-28 | Tvívetnis N-setnir og a-setnir dífenýlalkoxý ediksýru amínó alkýl esterar og lyf sem innihalda téð efnasambönd |
NO20035599A NO20035599D0 (no) | 2001-06-17 | 2003-12-16 | Deutererte N-substituerte og <alfa>-substituerte difenylalkoksyeddiksyreaminoalkylestere og medikamenter inneholdende disse |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10129832.3 | 2001-06-17 | ||
DE10129832A DE10129832A1 (de) | 2001-06-17 | 2001-06-17 | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002102743A2 WO2002102743A2 (de) | 2002-12-27 |
WO2002102743A3 true WO2002102743A3 (de) | 2003-03-13 |
WO2002102743A9 WO2002102743A9 (de) | 2004-03-11 |
Family
ID=7688891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2002/002260 WO2002102743A2 (de) | 2001-06-17 | 2002-06-17 | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040242887A1 (de) |
EP (1) | EP1397327A2 (de) |
JP (1) | JP2004534802A (de) |
KR (1) | KR20040020926A (de) |
CN (1) | CN1516684A (de) |
CA (1) | CA2451638A1 (de) |
CZ (1) | CZ20033365A3 (de) |
DE (1) | DE10129832A1 (de) |
HU (1) | HUP0400213A3 (de) |
IL (1) | IL159410A0 (de) |
IS (1) | IS7061A (de) |
NO (1) | NO20035599D0 (de) |
NZ (1) | NZ530352A (de) |
PL (1) | PL367218A1 (de) |
RU (1) | RU2004101229A (de) |
WO (1) | WO2002102743A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080146573A1 (en) * | 2006-12-04 | 2008-06-19 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted oxzolidinones |
US20090209608A1 (en) * | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
US20090062185A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched anidulafungin |
US20090069219A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched telavancin |
US20090076158A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched bicalutamide |
US20090075870A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched caspofungin |
US20090082419A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched tegaserod |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
WO2010138889A1 (en) * | 2009-05-28 | 2010-12-02 | Concert Pharmaceuticals, Inc. | Peptides for the treatment of hcv infections |
KR20120110090A (ko) * | 2009-09-28 | 2012-10-09 | 에프. 호프만-라 로슈 리미티드 | C형 간염 바이러스 복제의 신규한 마크로시클릭 저해제 |
CN102584592B (zh) * | 2011-12-28 | 2014-10-15 | 李进 | 一种氘代的拟除虫菊酯化合物及其制备方法和应用 |
EP2810936B1 (de) * | 2012-01-30 | 2017-11-22 | Taiho Pharmaceutical Co., Ltd. | Neuartige essigsäureesterverbindung oder salz davon |
CA2881182C (en) * | 2012-08-09 | 2021-01-26 | Chase Pharmaceuticals Corporation | Piperidinium quaternary salts |
CN105283444B (zh) * | 2013-05-30 | 2017-06-16 | 大鹏药品工业株式会社 | 氟代二苯乙醇酸酯化合物及其盐 |
CN107445798B (zh) * | 2016-06-01 | 2020-11-03 | 中国农业大学 | 一种α,α‐二氘代醇类化合物的合成方法 |
CN116078377B (zh) * | 2023-03-06 | 2023-06-27 | 泽升科技(广州)有限公司 | 一种负载催化剂催化制备氘代苯的生产工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD106642A1 (de) * | 1973-03-02 | 1974-06-20 | ||
DE2937489A1 (de) * | 1978-10-09 | 1980-04-17 | Apogepha Veb | Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6439873A (en) * | 1987-08-05 | 1989-02-10 | Sharp Kk | Synchronizing signal generating circuit |
EP0682649B1 (de) * | 1993-01-28 | 1998-09-02 | University Of Iowa Research Foundation | Deuteriertes sevofluran als inhalationsbetäubungsmittel |
DE4343838C2 (de) * | 1993-12-22 | 1998-07-09 | Lohmann Therapie Syst Lts | Deuteriertes Arzneimittel in transdermaler Applikation und Verfahren zu seiner Herstellung |
-
2001
- 2001-06-17 DE DE10129832A patent/DE10129832A1/de not_active Withdrawn
-
2002
- 2002-06-17 US US10/481,153 patent/US20040242887A1/en not_active Abandoned
- 2002-06-17 IL IL15941002A patent/IL159410A0/xx unknown
- 2002-06-17 RU RU2004101229/04A patent/RU2004101229A/ru not_active Application Discontinuation
- 2002-06-17 NZ NZ53035202A patent/NZ530352A/xx unknown
- 2002-06-17 CN CNA028121201A patent/CN1516684A/zh active Pending
- 2002-06-17 CA CA002451638A patent/CA2451638A1/en not_active Abandoned
- 2002-06-17 HU HU0400213A patent/HUP0400213A3/hu unknown
- 2002-06-17 WO PCT/DE2002/002260 patent/WO2002102743A2/de not_active Application Discontinuation
- 2002-06-17 EP EP02752970A patent/EP1397327A2/de not_active Withdrawn
- 2002-06-17 CZ CZ20033365A patent/CZ20033365A3/cs unknown
- 2002-06-17 PL PL02367218A patent/PL367218A1/xx not_active Application Discontinuation
- 2002-06-17 KR KR10-2003-7016441A patent/KR20040020926A/ko not_active Application Discontinuation
- 2002-06-17 JP JP2003505289A patent/JP2004534802A/ja active Pending
-
2003
- 2003-11-28 IS IS7061A patent/IS7061A/is unknown
- 2003-12-16 NO NO20035599A patent/NO20035599D0/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD106642A1 (de) * | 1973-03-02 | 1974-06-20 | ||
DE2937489A1 (de) * | 1978-10-09 | 1980-04-17 | Apogepha Veb | Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase |
Also Published As
Publication number | Publication date |
---|---|
CA2451638A1 (en) | 2002-12-27 |
CN1516684A (zh) | 2004-07-28 |
CZ20033365A3 (cs) | 2004-09-15 |
IL159410A0 (en) | 2004-06-01 |
PL367218A1 (en) | 2005-02-21 |
WO2002102743A9 (de) | 2004-03-11 |
NO20035599D0 (no) | 2003-12-16 |
RU2004101229A (ru) | 2005-06-27 |
KR20040020926A (ko) | 2004-03-09 |
HUP0400213A3 (en) | 2005-08-29 |
WO2002102743A2 (de) | 2002-12-27 |
EP1397327A2 (de) | 2004-03-17 |
IS7061A (is) | 2003-11-28 |
US20040242887A1 (en) | 2004-12-02 |
NZ530352A (en) | 2004-12-24 |
JP2004534802A (ja) | 2004-11-18 |
HUP0400213A2 (hu) | 2004-07-28 |
DE10129832A1 (de) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002102743A3 (de) | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel | |
EP1426375A3 (de) | Analgetische Spiroindolderivate | |
WO2005011653A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
WO2003000695A8 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
WO2005011655A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
DK1227806T3 (da) | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse | |
AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
WO2002070510A3 (de) | Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
EP1428821A8 (de) | Piperidin-4-ylamine mit analgetischer Wirksamkeit | |
GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
EP2767291A3 (de) | Behandlung der Glykogenspeicherkrankheit Typ II | |
WO2005054179A3 (en) | Hydroxamic acid esters and pharmaceutical use thereof | |
WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
SE0102440D0 (sv) | New compound | |
WO2001030331A3 (en) | Therapeutic compositions including protein kinase c inhibitors | |
WO2003000173A3 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
WO2001051489A3 (en) | Methods for lowering uric acid levels | |
CA2370501A1 (en) | Pharmaceutical composition for the therapy of lower urinary tract symptoms | |
CA2436537A1 (en) | Pharmaceutical compositions comprising tiotropium salts and antihistamines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003505289 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-3365 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037016441 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451638 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 159410 Country of ref document: IL Ref document number: 028121201 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1152/MUMNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 530352 Country of ref document: NZ Ref document number: 2002313447 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002752970 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 4,6,7,8,9, DESCRIPTION, REPLACED BY CORRECT PAGES 4,6,7,8,9; PAGES 13,15,16, CLAIMS, REPLACED BY CORRECT PAGES 13,15,16 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002752970 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10481153 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-3365 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 720/MUMNP/2004 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 530352 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 530352 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002752970 Country of ref document: EP |